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A B S T R A C T
Several research groups in Europe are active on different aspects of human picornavirus research. The AIROPico
(Academia-Industry R&D Opportunities for Picornaviruses) consortium combined the disciplines of pathogen-
esis, diagnostics and therapy development in order to fill the gaps in our understanding of how picornaviruses
cause human disease and how to combat them. AIROPico was the first EU consortium dedicated to human
picornavirus research and development, and has largely accelerated and improved R&D on picornavirus biology,
diagnostics and therapy. In this article, we present the progress on pathogenesis, diagnostics and treatment
strategy developments for human picornaviruses resulting from the structured, translational research approach
of the AIROPico consortium. We here summarize new insights in protection against infection by maternal or
cross-protective antibodies, the visualisation of interactions between virus and neutralizing antibodies by
cryoEM structural imaging, and the outcomes from a picornavirus-infected human 3D organoid. Progress in
molecular detection and a fast typing assay for rhinovirus species are presented, as well as the identification of
new compounds potentially interesting as therapeutic compounds.
1. AIROPico consortium overview
AIROPico, an interdisciplinary research network of four European
academic institutions and four companies, was run during 2014–2018
under the FP7 Marie Curie Industry-Academia Partnership and
Pathways (IAPP) program. The main aim was to promote research and
development on human picornaviruses by exchange of knowledge, ex-
perience and new research techniques between academy and compa-
nies (Fig. 1). The network was built upon long-standing academic and
academic-industry collaborations in the field of human picornavirus
research and/or diagnostic and antiviral development, with newly ac-
quired partners bringing in expertise on antibody production and pro-
filing. In this manner, a sustainable, interdisciplinary, integrated aca-
demia-industry consortium was established with experts in molecular
biology, structural biology, diagnostics, antibody production, antibody
profiling and antiviral development, to unravel mechanisms of human
picornavirus pathogenesis and to develop fast diagnostics, novel treat-
ment options and additional therapy strategies.
During 4 years, 22 fellows in different career stages (from techni-
cians to senior staff members) were exchanged between academic and
industry partners (Fig. 1) for periods ranging from 2 months to 2 years.
A total of 117 person months divided over 30 secondments were exe-
cuted. In addition, 6 post-doctoral researchers were recruited to AIR-
OPico projects for periods ranging from 12 to 24 months. Together they
have executed a pre-designed plan, which included work plans for
fellows and recruits, and descriptions of tasks with deliverables, divided
over 5 work packages. The fellows were part of the projects in WP 1–3
which aimed to unravel pathogenesis and accelerate detection and
treatment developments for human picornavirus infections.
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2. Scientific results from the AIROPico consortium
2.1. Prevalence and protection against disease
As global efforts to eradicate poliovirus are successfully on their
way, other picornaviruses are still circulating worldwide (Table 1).
Large outbreaks of enterovirus A71 (EV-A71) in Asia, EV-D68 in the US,
Europe and Asia and human parechovirus 3 (PeV-A3) in Australia
(Solomon et al., 2010) (Pons-Salort et al., 2015) (Khatami et al., 2015),
all associated with severe disease, show the importance of the non-polio
picornaviruses as threat to human health (Harvala et al., 2018). The
host response to infection is mainly humoral: neutralizing antibodies
(nAbs) are elicited against a specific virus type leading to virus clear-
ance. The protective nAb response is often type-specific and does not
necessarily provide protection against other types of viruses from the
same geno-group (Anastasina et al., 2017; Karelehto et al., 2017). The
role of genotype-specific neutralizing in controlling the neurotropic
picornaviruses EV-A71, EV-D68, and PeV-A-3 was reviewed recently in
(Anastasina et al., 2017).
Outbreaks of EV-A71 in Asia are related to high illness and death
rates among children, but up to now such outbreaks have not occurred
in Europe (Chang et al., 2016). To gain insight into the potential threat
for the population of Europe, we determined the neutralizing activity in
batches of pooled immunoglobulins (IVIg) and individual serum sam-
ples from donors in the Netherlands against EV-A71 strains isolated in
Europe and in Asia (Van der Sanden et al., 2016). All IVIg batches and
41%, 79%, and 65% of serum samples from children ≤5 years of age,
women of childbearing age, and HIV-positive men, respectively,
showed high neutralizing activity against a Dutch C1 strain, confirming
widespread circulation of EV-A71 in the Netherlands. Asian B3-4 and
C4 strains were efficiently cross-neutralized, predicting possible pro-
tection against extensive circulation and associated outbreaks of those
types in Europe. However, C2 and C5 strains that had few mutations in
the capsid region consistently escaped neutralization, emphasizing the
importance of monitoring antigenic diversity among circulating EV-71
strains.
We showed previously that the Parechovirus (PeV) group is as pre-
valent as the EV group, being the second leading cause of viral CNS
infections in neonates (Wolthers et al., 2008). Despite their apparent
clinical significance, less is known about their epidemiology and pa-
thogenesis than for the other picornaviruses. PeV-A1 is the most com-
monly found followed by PeV-A3. While PeV-A1 is associated with mild
disease in children>6 months, PeV-A3 is associated with severe dis-
ease in neonates (Benschop et al., 2006). We conducted a prospective
case-control study of Dutch mother-infant pairs to investigate if ma-
ternal nAbs against HPeV-A1, 3 and 4 (the most prevalent PeVs in the
Netherlands), protect young Dutch infants from severe disease related
to PeV infection (Karelehto et al., 2018b). No differences in nAb ser-
oprevalence against PeV-A1 or PeV-A4 could be detected between case
and control infants or mothers. In contrast, the PeV-A3 nAb ser-
oprevalence was significantly lower in PeV-A3-infected infants and
their mothers. Our results suggest that young Dutch infants are
Fig. 1. Principle of the AIROPico network: (red) 4 companies and (white) 4 academic groups, (right) exchanging 22 fellows in total.
Table 1
Background on the human picornavirus infections addressed in AIROPico.
Genus Enterovirus Parechovirus
Species Human Enterovirus A-D (EV-A/D) Human Rhinovirus A-C (RV-A/C) Human Parechovirus A (PeV-A)
Genotypes 113 types: poliovirus 1–3, coxsackieviruses A and B,
echovirus 1–34, enterovirus 68-119
167 types 19 types
Disease association Paralytic disease, meningitis, encephalitis,
myocarditis, neonatal sepsis, hand-foot-mouth
disease, hepatitis, conjunctivitis, respiratory disease,
fever.
Common cold, rhino-sinusitis, lower
respiratory disease, exacerbation
asthma/COPD.
Mild respiratory and gastrointestinal disease, neonatal
sepsis, meningitis, encephalitis, myocarditis.
Epidemiology Fecal-oral transmission, circulation late Summer-Fall.
Frequent worldwide circulation, leading causes of
viral meningitis (US/Europe) and HFM disease
outbreaks (Asia).
Respiratory transmission. Frequent
worldwide circulation throughout year,
responsible for > half of all ‘common
cold’ cases.
Fecal-oral transmission, circulation Summer-Fall.
Among the most frequently circulating picornaviruses
in children in Europe/US. Worldwide less data than for
EVs but circulation observed in all continents.
Detection 5′UTR EV RT-qPCR from patient samples: respiratory
swab, stool, CSF, vesicle swab.
Genotyping by VP1 sequencing
Virus culture still done but far less sensitive
5′UTR RV RT-qPCR from respiratory
samples (swab, aspirates, BAL)
Typing by VP2/4 sequencing but mostly
not performed. EV and RV 5′UTR PCRs
can cross react.
Virus culture obsolete.
5′UTR PEV-specific RT-qPCR from patient samples:
respiratory swab, stool, CSF, vesicle swab. Genotyping
by VP1 sequencing.
Many PeVs uncultivatable
State-of-the-art EV-A71 outbreaks in Asia and current local vaccine
development. EV-D68 outbreaks US/Europe
associated with paralytic disease.
No treatment available. Standard care supportive,
IVIG can be considered
Association of RV-C with more severe
disease under debate.
Association of RV with asthma
development.
No treatment available.
PeV-A3 associated with neonatal sepsis and meningitis.
Outbreaks of PeV-A3 in Australia with a recombinant
strain.
No treatment available. Standard care supportive, IVIG
can be considered.
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protected against severe disease related to PeV-A1 and PeV-A4 by
maternal nAbs, but less against PeV-A3, explaining the distinct age
distributions and disease severity profiles of children infected with
these PeV genotypes.
Recent PeV-A3 outbreaks in Australia suggest lower population
immunity compared to regions with endemic PeV-A3 circulation.
However, a serosurvey among Dutch, US and Australian populations
prior to and after the Australian outbreak in 2013 showed high PeV-A3
neutralizing antibody prevalence across all regions and time periods
(68.9%), indicating long-term widespread PeV-A3 circulation
(Karelehto et al., 2018b). This shows that the outbreaks were not
caused by a lack of nAb protection against the outbreak strain.
We previously observed apparent discrepancies between ser-
opositivity rates for PeV-A3 nAbs in Japan (high) and in the
Netherlands and Finland (both low) (Tanaka et al., 2016; Westerhuis
et al., 2013). This was explored further by determining the neutralizing
activity of Japanese and Dutch IVIg, aPeV-A3 polyclonal Abs (pAb), and
a human aPeV-A3-specific monoclonal Ab (mAb), against the PeV-A3
A308/99 prototype strain and clinical isolates from Japan, the Neth-
erlands and Australia (Karelehto et al., 2017). All PeV-A3 isolates were
highly neutralized by the polyclonal pAb (pAb) whereas neutralization
titers of IVIG varied; the mAb exclusively neutralized the A308/99
strain (Fig. 2). Mapping of the amino acid variation among a subset of
the PeV-A3 strains on a PeV-A3 capsid structure revealed that the
majority of the surface-exposed amino acid variation was located in
viral protein (VP)1. Furthermore, amino acid mutations in a variant
resistant to neutralization by the mAb indicated the location for po-
tential antigenic determinants. Virus aggregation and the observed
antigenic diversity in PeV-A3 can thus explain the varying levels of nAb
seropositivity reported in previous studies (Tanaka et al., 2016;
Westerhuis et al., 2013).
2.2. PeV structures and interactions with human monoclonal antibodies
Knowledge of the molecular structure of viruses is pivotal in un-
derstanding structure-function relationships, virus entry and assembly.
By the synergistic combination of X-ray crystallography, three-dimen-
sional cryo-electron microscopy (3DEM), homology modelling and in-
teraction studies with Abs we were able to investigate the mechanism of
action of neutralizing and broadly specific Abs (Karelehto et al., 2017;
Shakeel et al., 2016, 2017; Shakeel et al., 2015) (Domanska et al.,
2018). As viruses evolve, in reaction to the host immune response, the
capsid structures helped us to map the antigenic variability of emergent
isolates (Karelehto et al., 2017). We developed a high-throughput next
generation phage display method (MVA) to delineate PeV-specific im-
munoprofiles. As a result of the pilot study of infected Dutch mothers,
several potential epitopes were identified on structural and non-struc-
tural proteins of HPeV1 and HPeV3 (Anastasina et al., unpublished).
This work is important for predicting how well diagnostic and ther-
apeutic tools based on recognition of that surface will function.
Three PeV structures were solved by 3DEM: two PeV-A3 and one
PeV-A1. By binding human mAb fragments to the viruses and repeating
the structure determination we could also determine the viral epitopes
and Ab paratopes (Kalynych et al., 2015; Seitsonen et al., 2010; Shakeel
et al., 2016, 2017; Shakeel et al., 2015) (Domanska et al., 2018). Both
PeV-A1 and PeV-A3 have the conserved picornavirus capsid structure
containing 60 copies each of VP0, VP1 and VP3 arranged in a T= 1
capsid. Unlike other picornaviruses, VP0 is not cleaved into VP2 and
VP4. The PeV structure has three distinct features: firstly, 25% of the
PeV RNA genome is highly ordered, interacting with conserved regions
of the capsid proteins VP1 and VP3. Secondly, the VP0 N terminus
stabilizes the capsid inner surface, in contrast to other picornaviruses
where on expulsion as VP4, it forms an RNA translocation channel.
Lastly, VP1's hydrophobic pocket, the binding site for the anti-
picornaviral drug pleconaril, is blocked and thus inappropriate for an-
tiviral development. Together, these results suggest a direction for
development of nAbs, antiviral drugs based on targeting the RNA–-
protein interactions and dissection of virus assembly on the basis of
RNA nucleation. This work was followed by analysis of the repeating
RNA motif in the PeV genome that binds to the capsid, where we re-
vealed that the capsid assembly is driven by the RNA-protein interac-
tions and by intrinsically disordered regions of the capsid (Shakeel
et al., 2017) (Shakeel et al., 2018) (Domanska et al., 2018).
We identified two potential therapeutic human mAbs with the ca-
pacity to neutralize PeV-A1. Strikingly, these mAbs have the capacity to
Fig. 2. Neutralization capacity of a polyclonal rabbit PeV-A3 antiserum (PeV-
A3 pAb), Dutch (NL) and Japanese (JP) IVIG batches and a human AT12-015
monoclonal antibody (PeV-A3 mAb) against a panel of 25 PeV-A3 isolates
collected between 1989 and 2015. (A) Heat map representation of log2-trans-
formed nAb titers against individual PeV-A3 isolates arranged based on year of
isolation. (B) Comparison of prototype PeV-A3 A308/99 strain nAb titers
against the median nAb titers (with interquartile range) of the clinical PeV-A3
isolates. Samples were grouped by the geographical location of isolation (Dutch
isolates; NL, Japanese isolates; JP and Australian isolates; AUS). Positivity was
defined as a titer ≥5 log2. PeV-A3 isolate group median nAb titers with in-
terquartile range were compared by Kruskal-Wallis test with Dunn's post hoc
analysis (significance level p < 0.05). Taken from (Karelehto et al., 2017) with
permission.
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neutralize other PeVs as well (Westerhuis et al., 2015). We now know
exactly which viral structures are targeted by the two mAbs, and the
mechanism through which these mAbs neutralize the virus. One mAb
binds at exactly the same spot that is used by the virus to attach to
human target cells via integrins (Merilahti et al., 2016). Hence, binding
of the mAb to the virus renders the virus unable to attach to the human
target cells resulting in a neutralized virus. The second mAb binds to a
conformational epitope stabilizing the capsid so that the expansion
required to release the genome into the cell, is inhibited (Shakeel et al.,
2015). For PeV-A3, the mAb (AT12-015) that neutralized the prototype
strain A308/99 but none of the recent clinical isolates tested (Karelehto
et al., 2017; Shakeel et al., 2016) was used (Domanska et al., 2018). A
high-resolution structure of PeV-A3 A308/99 in complex with the Fab
fragments was determined using 3DEM to 2.8 Å resolution. The con-
formational epitope for mAb AT12-015 is shown in Fig. 3 in yellow on
the surface of the virus. We showed that Mab decoration blocks binding
of PeV-A3 A308/99 to cultured human intestinal cells (Domanska et al.,
2018). The structure revealed that the binding energy of the interaction
is stabilized by multiple hydrogen bonds and salt bridges, which were
readily destroyed by the amino acid changes in the capsid proteins
found in escape mutants, and by changes in the C-terminus of VP1 that
extrudes from the capsid surface just next to the epitope.
This is a first step towards understanding the molecular basis of the
specificity of binding of (therapeutic) mAbs to emergent viruses, and
optimizing this computationally in conjunction with conventional
screening methods is imperative, to drive the design for lead com-
pounds.
2.3. Human organoid cultures to study infection
Human picornaviruses are transmitted either via the fecal-oral route
or by respiratory transmission. Replication starts in the respiratory tract
and/or the gastro-intestinal tract, followed by spreading via the blood
to infect various target organs such as skin, heart, or brain as sum-
marized in Table 1. Except for the rhinoviruses (RVs), the human pi-
cornaviruses have a broad tissue tropism, and while several cellular
receptors have been identified and studied in cell models (Baggen et al.,
2018; Heikkilä et al., 2016; Merilahti et al., 2016), mechanisms of entry
events and the role of previously identified receptors in native tissues
are largely unknown.
Advances in 3D cell culture or organoid technology (Clevers, 2016)
make it possible to culture human mini-organs, e.g. gut or respiratory
epithelial tissue, in a dish (Fig. 4A and B). These organoid models open
up a new way for studying virus-host interactions without the use of
immortalized cell lines or animal models.
It has been suggested that infection via the respiratory tract instead
of the gut may predispose for infection of the CNS (Zhang et al., 2011).
In EV-A71 infections, pulmonary edema has been described as a deadly
complication. Therefore, the human airway seems an important site for
human picornaviruses. We infected a newly developed human lung
organoid model (Sachs et al., 2018) with EV-A71 to test susceptibility
and infection kinetics in human respiratory tissue (Van der Sanden
et al., 2018). We could now for the first time show in a human model
that EV-A71 replication kinetics are strain dependent, while the infec-
tion kinetics of the different strains was comparable in unrelated Cau-
casian adult donors. The glutamine (Q) at position 145 of the VP1
capsid protein was identified as a key determinant of infection efficacy.
Remarkably, this is in agreement with the observation that presence of
the EV-A71 VP-145Q strain in patients was associated with more severe
disease. These promising results obtained with organoids underline
their potential to translate to the human in vivo situation is higher than
for cell lines or animal models.
To study PeV entry in the respiratory epithelium, we infected upper
human airway epithelial (HAE) cultures (Karelehto et al., 2018a)
(Fig. 4C) . In contrast to what was expected, both PeV-A1 and PeV-A3
genotypes infected HAE preferentially from the basolateral surface,
while the progeny virus was shed towards the apical side, arguing
against the respiratory tract as a primary entry site for PeV. Confocal
microscopy revealed the target cells to be the p63⁺ basal cells for both
viruses. Blocking the known receptors for PeV-A1, αV integrins (ITG)
and heparan sulfate (HS) had no effect on the replication of either virus;
this was expected for PeV-A3, which lacks the RGD motif necessary for
integrin binding (Merilahti et al., 2012; Seitsonen et al., 2010). How-
ever, ineffective blocking of the known receptors for PeV-A1 indicates
that unidentified receptors play a role in entry of primary replication
sites in vivo.
In summary, these results show the potential of 3D cell cultures to
study virus-host interaction for human picornaviruses.
2.4. Rapid generation of picornaviral cDNA clones
With the advent of Next Generation Sequencing methods and the
interest to analyze novel pathogenic picornavirus isolates, it is im-
portant to have less time-consuming and resource-saving methods to
generate templates for sequencing and mutagenesis studies. In prior
work a pre-existing cDNA clone of coxsackievirus A9 (CVA9) was used
as a template to develop a method for rapid generation and recovery of
T7 promoter-tagged full-length CVA9 clones (Heikkilä et al., 2011).
Within AIROPico we further developed the method and tested either
alone or in combination high fidelity PCR enzymes and reverse tran-
scriptases to identify the key enzymes for rapid and sensitive amplifi-
cation of full-length viral amplicons. We found two PCR enzymes that
were superior in their ability to amplify 7.5 kb fragments; such enzymes
were able to multiply picornaviral cDNA clones with sensitivity of 1000
Fig. 3. Interactions between Fab AT12-015 and PeV-A3. The Fab binds to an
epitope extended across neighboring asymmetric units in the assembled virion.
Two asymmetric units are shown. VP0, VP1, VP1′, and VP3′ residues partici-
pating in Fab heavy and light chain binding are highlighted in yellow. Blue
VP0, green VP1, and light blue VP3. Taken from (Domanska et al., 2018) with
permission. PDB entry ID 6GV4 and EMDB entry ID EMD-0069 (Deposition ID
D_1200010538).
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cDNA copies. In combination with RT enzyme, in vitro transcribed,
purified viral RNA was converted to PCR with highest sensitivity of
10,000 RNA copies (manuscript in preparation). This easily corresponds
to the copy number of most cell cultivated picornaviruses and many
clinical specimens suggesting that it will be feasible to try recovery of
picornaviruses directly from clinical specimens. To enable cloning and
conversion of picornaviral cDNA clones into viable virus we tested
different strategies and optimized a method that allows direct genera-
tion of infectious picornavirus variants in a few weeks instead of using
slow and tedious subcloning strategies.
2.5. Human picornavirus detection
We aimed to develop rapid molecular diagnostics assays for multi-
plexing and typing of human picornaviruses and to develop and test a
point of care (POC) assay utilizing picornavirus-specific Abs. The aim
was also to evaluate the performance of assays in a clinical setting and
by using clinical specimens. While there are several POC tests for the
detection of selected respiratory viruses such as respiratory syncytial
virus (RSV) and influenza virus (Bruning et al., 2017b), there are also
test systems for a panel of respiratory viruses. AIROPico partner ArcDia
has developed an assay technique (mariPOC®), which is a rapid and
fully automated POC test system for multi-analyte testing of pathogens
from swab samples within 20min (Sanbonmatsu-Gámez et al., 2015).
This assay depends on Abs for capture and complexing of viral particles
for their detection by separation-free two photon excitation
fluorescence technology (Koskinen et al., 2007). The easy-to-use system
allows random-access analysis of patient samples and can easily be
operated by lab technicians or nurses in polyclinic departments. Within
AIROPico, a clinical study was set up in the general practitioner's office
to assess the value of viral diagnostics in the GPs office and to gain more
insight into the epidemiology of respiratory viruses in a non-hospital
patient population. It was shown that fast diagnostics with the mar-
iPOC® for selected respiratory viruses contributed to a precise and
evidence-based diagnosis of respiratory tract infections, which could
have impact on prescription of antibiotics by GPs, but that its impact on
clinical decision making should be further assessed (Bruning et al.,
2017a) In addition, the studies showed that the majority of the re-
spiratory tract infections were caused by human picornaviruses (parti-
cularly RVs) (Bruning et al., 2018) suggesting that there is a need for a
specific picornaviral POC assay.
One of the most demanding tasks within AIROPico was to develop
specific picornavirus rapid POC assays based on antigen detection.
There were two approaches used to identify specific pan-picornavirus
Abs: 1) identification and testing of commercial Ab preparations and 2)
design and generation of new Abs. A review of the commercially-
available Abs resulted in the identification and testing of several com-
mercial pan-entero Ab candidates for use in antigen testing and paved
the way for identification of common epitopes.
For in-house Ab development we used in silico analysis of picorna-
viral sequences by means of bioinformatics and chose several target
proteins to be generated recombinantly in E. coli. In parallel,
Fig. 4. Organotypic cell culture models recapitulate characteristics of in vivo tissues. (A) Human airway epithelium (HAE) culture model. Image adapted from
STEMCELL Technologies Inc. All rights reserved, image copyright © 2018 by STEMCELL Technologies Inc. (B) Intestinal organoids from (O'Rourke et al., 2016) (C)
PeV target p63 positive basal cells in the airway epithelium. Confocal image stacks of PeV1- and PeV3-infected HAE cultures triple-stained by ciliated cell marker β-
tubulin (red), basal cell marker p63 (purple) and HPeV antibody (green); adapted from (Karelehto et al., 2018a).
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representative viruses were purified by gradient ultracentrifugation to
be used as immunogens. While most attempts to generate mono-specific
Abs failed due to insufficient immune response, we can report one
successful case. Based on prior studies and bioinformatics analysis PeV
VP0 protein was chosen as an immunogen to develop mono-specific Abs
to PeVs. PeV-VP0-immunized mice gave positive responses on both
ELISA and an immunofluorescence assay. Hybridoma cell lines were
generated from PeV-A1-VP0 immunized animals, and one positive
monoclonal cell line was rescued (BCN4823, AntibodyBcn). In parallel
to animal immunizations, we used synthetic scFv antibody libraries to
screen Abs against recombinant PeV-VP0. Synthetic scFv PeV-VP0 an-
tibodies also gave good response on ELISA and immunofluorescence
assays. Ab epitopes on the viral surface were mapped by cryoEM. The
aPeV-Abs were further tested at ArcDia using the mariPOC platform but
the Abs did not enable the development of a wash-free sandwich im-
munoassay. This suggested that anti-parechoviral Abs likely had affi-
nities too low to give sufficient sensitivity, even though they gave good
response in ELISA and IFA. Nevertheless, these data lay a solid
groundwork for future Ab and assay optimization projects.
Molecular diagnostics and more specifically reverse transcription
real-time quantitative polymerase chain reaction (RT-qPCR) has be-
come the state-of-art technique in detection of pathogens. RT-qPCR has
largely replaced cell culture and microscopical methods because it is
highly sensitive in detecting picornaviruses in clinical samples. In ad-
dition, molecular diagnostics can be used to detect genotypes such as
RV-C that cannot be cultured. For molecular diagnostics, we worked on
both typing and multiplexing methods. Fast typing of picornaviruses in
conditions such as neonatal disease or CNS infections would influence
clinical decision making and furthermore provide epidemiological data
for outbreak management. While in many hospital laboratories PCR is
the current method-of-choice for picornavirus diagnostics (Harvala
et al., 2018), picornavirus typing is not routinely performed because
typing protocols have not yet been standardized.
In AIROPico we implemented both sequence-specific detection and
sequencing strategies for typing the viruses. A Chipron array utilizing
several sets of type-specific probes to detect and distinguish between
RV-A, RV-B and RV-C, reduces the time to results considerably. The
developed assays were validated in a clinical setting (Westerhuis et al.,
2018). In parallel, we developed a low cost workflow for entero- and
rhinoviral typing using RT-qPCR, which should expedite the identifi-
cation of positive samples after PCR amplification and subsequent
Sanger sequencing. Similarly to cDNA cloning, this method is depen-
dent on long distance PCR enzymes that are capable of amplification
the target picornaviral sequences used for typing (Chansaenroj and
Susi, 2018. Unpublished). In addition to typing procedures, TIB MOL-
BIOL developed novel multiplex respiratory panels including specific
entero- and rhinovirus assays or a panPicorna test followed by running
specific assays in order to improve productivity and differentiation
between entero- and rhinovirus. The assays have been validated in two
typing laboratories against their reference assay with repeat testing of
diagnostic samples.
2.6. Antiviral strategies to fight enterovirus infection
Today, more than 20 different drugs for the treatment of HIV in-
fections are approved; further potent antivirals for treatment of infec-
tions with herpesviruses, hepatitis B and C viruses, and influenza
viruses are available or in clinical development (Debing et al., 2015).
For human picornaviruses, small molecules that block in vitro replica-
tion have been reported. Although these compounds were designed
with the aim to treat infected patients, none of them reached the
market. In many cases, toxicity or poor pharmacokinetics posed major
issues (Bauer et al., 2017) (van der Linden et al., 2015).
However, the pressure to develop anti-picornavirus drugs has
increased and hence, the constraints for such drugs in terms of toler-
ability may be reconsidered. Especially in Asia, EVs have become a
major threat in the young population and clinicians urgently call for an
efficient and selective treatment. Likewise, the need for a treatment to
block RV infections has also increased since it is now widely recognized
that these viruses are implicated in exacerbations of chronic lung dis-
eases (Zwaans et al., 2014).
RV infections do not only cause common colds, but may also trigger
severe exacerbations of asthma and chronic obstructive pulmonary
disease (COPD). Even though RVs have been the focus of extensive drug
development efforts in the past (such as pleconaril, which has been
withdrawn), no anti-rhinoviral drug has made it to market. In the past,
VP1 has been shown to be an important target for the development of
antiviral molecules. Furthermore, many different chemical scaffolds
appear to possess the properties that are required to inhibit virus re-
plication by this mechanism of action. An analogue of the RV inhibitor
pirodavir, ca603, a molecule with a modified linker structure, showed
antiviral activity against a panel of RVs and EVs. The compound binds
to VP1 in lipid factor pocket and thus stabilizes the viral capsid (Lacroix
et al., 2015).
We initiated an antiviral development program against picorna-
viruses. To start this antiviral program, a diverse set of several thousand
chemical compounds was tested in an antiviral screening against
Coxsackie B viruses (CVB). We identified several small molecules that
had pan-enterovirus activity, affecting CVB3, CVB1, CVB6, CVB4,
CVB5. A time-of-drug addition, experiment revealed that the most in-
teresting compound targets CVB3 replication at the entry stage of the
viral cycle as most of the antiviral activity was lost when the compound
was added 2h post-infection. The structure determination of CVB3 with
the compound bound by 3DEM proved that it has a unique antiviral
profile with a different binding mode to those compounds that bind in
the lipid factor pocket like ca603 described above. Further, we could
predict which other picornaviruses would be inhibited. This work has
led to a very promising small hit explosion with several more inter-
esting leads (Ma et al., 2017) (Abdelnabi et al.,submitted).
In addition to CVB inhibitors, an effort was undertaken to find an-
tivirals against PeV infections. Convenient, robust and reproducible
assays systems were elaborated, which were validated for antiviral
screening purposes. This will now allow to run screenings campaigns to
identify inhibitors of PeV replication and hence to initiate drug devel-
opment programs against this important human pathogen.
We found that tryptophan dendrimers that inhibit HIV replication
(by binding to the envelope glycoproteins gp120 and gp41), un-
expectedly, are also potent, specific, and selective inhibitors of the re-
plication of the unrelated EV-A71. A consensus compound that was
synthesized on the basis of the structure-activity relationship analysis of
a series of dendrimers inhibited a large panel of clinical isolates in the
low-nanomolar/high-picomolar range (Rivero-Buceta et al., 2016).
Next to the direct exploration of antiviral activity, several attempts
were made to develop antiviral assay systems for RV-C. This is a highly
relevant virus that remains challenging to grow in the lab, which limits
the research towards therapies. The approach taken was to generate
chimeric viruses with the RV-C 2C-gene or the RV-C polymerase-gene in
a background of RV-A or RV-B. The work showed that chimeric RV-A/C
or RV-B/C can be made, but currently they are hampered by an im-
paired viral replication. This impaired virus replication prohibited the
study of antiviral activity. These results suggest that inter-typical ex-
changes of specific viral non-structural proteins generates chimeric
constructs with defects in replication, thus not suitable models for an-
tiviral studies (manuscript in preparation).
As the clinical relevance of picornaviruses has become more ap-
parent, it is evident that the search for novel, potent and selective
therapies to tackle picornavirus infections is one of the major chal-
lenges for the years to come in the field of antivirals.
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3. Lessons learned from the experience of the AIROPico
consortium
In the Marie Curie FP7 Industry-Academic Partnership consortia,
partners need to exchange knowledge and human resources to obtain
the research goals. The main tool is to bring employees from academia
to industry and vice versa to obtain and transfer knowledge to their host
institute. In addition, postdoctoral researchers can be recruited, but this
is secondary to the secondments. While all AIROPico partners were
willing to accept fellows on secondments for short (2–4 months) or long
term fellowships (6–24 months), the main challenge was to have suf-
ficient capacity to exchange fellows from the industry partners to the
academic partners. Another challenge was to find suitable fellows for
secondments, since the EU criteria for employees eligible for second-
ments are strict: while fellows are allowed to come from different career
backgrounds, they have to be employed by the sending institution for at
least one year, and employment after a secondment needs to be guar-
anteed for at least another year. Since many researchers are employed
on short contracts in academia, it is a challenge to find employees who
are eligible, and who are willing to go abroad and work and live in a
different environment. The AIROPico partners were very good in
identifying potential fellows, and motivating them to do secondments.
The key to success in this is well-preparedness: projects and workplans
were discussed and documented before starting a new project, and
contacts between the sending institute, the hosting institute and the
fellow was established at least 3 months before a secondment, if pos-
sible, by a site visit. Another important factor for a successful con-
sortium is the monitoring of progress. Progression of secondments and
well-being of the fellows was monitored by the supervisors as well as by
the WP leader, who reported progression of the individual projects in
monthly teleconferences with all WP leaders and the coordinator. End
reporting was done in a written report by all fellows, and for longer
secondments, progression reports from the fellow were mandatory
every 3 months. Fellows presented the results as well as personal ex-
periences of their secondment in the yearly consortium meetings. This
way, the overall progression within the consortium was monitored and
potential problems could be identified and dealt with rapidly.
The success of the consortium is reflected not only by the scientific
output as described in the previous sections, but by non-scientific
output as well (Wolthers and Geraets, 2016). Over 4 years, the majority
of the secondments (96%) was performed as planned. AIROPico meet-
ings, organized according to the original plan comprising of a Kick Off
meeting, 4 workshops and an End meeting, were attended by the ma-
jority of consortium members and were valued highly. Importantly,
most of the fellows that had been on secondments reported very posi-
tive experiences both professionally and personally. People liked the
change of working environment, calling it inspirational and a good way
to learn new techniques and new ways of working and learning. Fellows
enjoyed their increased networks and, on several occasions, paid short
informal visits to the hosting sites. Cultural differences (between
countries, and between industry-academic environments) were experi-
enced as very positive and refreshing, and most fellows liked living in
another European city or town without experiencing many problems in
adapting. The most reported problems were the financial complexity of
the secondments, and finding an affordable spot to live.
Of the six recruited post-doctoral fellows (3 females, 3 males), 4
stayed in academic research, 1 stayed in industry, and 1 switched from
academia to industry, indicating the successful career paths for Marie
Curie fellows.
AIROPico partners valued the intensive collaborations and network
formation, and recognized the positive effects on seconded employees
in terms of knowledge transfer and broadened experience, as well as the
gain of hosting fellows bringing in new ideas, techniques and experi-
ences, all of which compensated for the ‘loss of an employee’ when an
employee had to go on secondment.
In conclusion, the AIROPico consortium has resulted in intensive
collaborations on research and development on human picornavirus
biology, detection and antiviral compound development. This has led to
long-lasting collaborations between partners that will be extended in
projects on development of POC testing, exploitation of organoid
models for virology, and combining antiviral compound development
with structural biology.
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